Trial Profile

A retrospective cohort study to characterize demographics, use of acute and preventive medication, and healthcare resource utilization of adults with migraine who received calcitonin gene- related peptide monoclonal antibody

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eptinezumab (Primary) ; Erenumab (Primary) ; Fremanezumab (Primary) ; Galcanezumab (Primary)
Indications Migraine
Focus Therapeutic Use

04 Aug 2022 New trial record
12 Jun 2022 Results presented at the 64th Annual Scientific Meeting of the American Headache Society

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com